Device Prom Song: Looks Like We Made It

A year ago, things looked bleak everywhere, including devices. But investors and executives battened down the hatches, tightened their belts, and adopted every other conceivable austerity-tied cliché. Things now are beginning to look up…a little.

Eighteen months ago, after the world's economic house of cards collapsed, many in the device industry shifted into damage-control mode. For venture capital investors, triaging was the practice of the day as partners picked through their portfolios, with an eye toward identifying which companies lived and which would be shut off from any further help, aka capital. Chief executives, meanwhile, down-shifted operations, preparing to get by with very little new capital, if any at all. The medical device industry, in short, was preparing for the worst: the onset of another dreary period in which capital and exiting opportunities would be scarce.

Each of these measures was done with the idea of surviving. ( See "A New Chapter for Device VCs?," START-UP,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By 

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By 

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By 

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.

More from Business

Sanofi Shares Slide Despite Amlitelimab Eczema Win

 
• By 

The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.

Zydus Beats Gilead, Ipsen On Cholangitis Primary Endpoint But Pruritus Data Is Key

 
• By 

Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.

Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data

 

R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.